SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Karnevi Emelie)
 

Sökning: WFRF:(Karnevi Emelie) > (2017) > The clinical import...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006082naa a2200433 4500
001oai:lup.lub.lu.se:7d4eeef6-5d4d-4877-8fb6-1b1099c0b9d2
003SwePub
008170726s2017 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:136267939
0247 a https://lup.lub.lu.se/record/7d4eeef6-5d4d-4877-8fb6-1b1099c0b9d22 URI
0247 a https://doi.org/10.1186/s12967-017-1256-y2 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1362679392 URI
040 a (SwePub)lud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Lundgren, Sebastianu Lund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Personalized Pathology & Cancer Therapy,Lund University Research Groups4 aut0 (Swepub:lu)se2285lu
2451 0a The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype
264 c 2017-07-03
264 1b Springer Science and Business Media LLC,c 2017
520 a Background: Dendritic cells (DC) and tumour-associated macrophages (TAM) are essential in linking the innate and adaptive immune response against tumour cells and tumour progression. These cells are also potential target for immunotherapy as well as providing a handle to investigate immune status in the tumour microenvironment. The aim of the present study was to examine their impact on prognosis and chemotherapy response in periampullary adenocarcinoma, including pancreatic cancer, with particular reference to morphological subtype. Methods: The density of tolerogenic immature CD1a+ dendritic cells (DC), and MARCO+, CD68+ and CD163+ tissue-associated macrophages (TAM) was analysed by immunohistochemistry in tissue micro arrays with tumours from 175 consecutive cases of periampullary adenocarcinoma who had undergone pancreaticoduodenectomy, 110 with pancreatobiliary type (PB-type) and 65 with intestinal type (I-type) morphology. Kaplan-Meier and Cox regression analyses were applied to determine the impact of immune cell infiltration on 5-year overall survival (OS). Results: High density of CD1a+ DCs was an independent prognostic factor for a reduced OS in PB-type but not in I-type tumours (adjusted HR = 2.35; 95% CI 1.13-4.87). High density of CD68+ and CD163+ TAM was significantly associated with poor OS in the whole cohort, however only in unadjusted analysis (HR = 1.67; 95% CI 1.06-2.63, and HR = 1.84; 95% CI 1.09-3.09, respectively) and not in strata according to morphological subtype. High density of MARCO+ macrophages was significantly associated with poor prognosis in I-type but not in PB-type tumours (HR = 2.14 95% CI 1.03-4.44), and this association was only evident in patients treated with adjuvant chemotherapy. The prognostic value of the other investigated immune cells did not differ significantly in strata according to adjuvant chemotherapy. Conclusions: The results from this study demonstrate that high infiltration of tolerogenic immature DCs independently predicts a shorter survival in patients with PB-type periampullary adenocarcinoma, and that high density of the MARCO+ subtype of TAMs predicts a shorter survival in patients with I-type tumours. These results emphasise the importance of taking morphological subtype into account in biomarker studies related to periampullary cancer, and indicate that therapies targeting dendritic cells may be of value in the treatment of PB-type tumours, which are associated with the worst prognosis.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Karnevi, Emelieu Lund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Personalized Pathology & Cancer Therapy,Lund University Research Groups4 aut0 (Swepub:lu)med-ekn
7001 a Elebro, Jacobu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-jce
7001 a Nodin, Björnu Lund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Personalized Pathology & Cancer Therapy,Lund University Research Groups4 aut0 (Swepub:lu)immu-bnn
7001 a Karlsson, Mikael C.I.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Eberhard, Jakobu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-jeb
7001 a Leandersson, Karinu Lund University,Lunds universitet,Cancerimmunologi, Malmö,Forskargrupper vid Lunds universitet,Cancer Immunology, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)immu-kpe
7001 a Jirström, Karinu Lund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Personalized Pathology & Cancer Therapy,Lund University Research Groups4 aut0 (Swepub:lu)pat-kji
7102 a Personlig patologi och cancerbehandlingb Forskargrupper vid Lunds universitet4 org
7730 t Journal of Translational Medicined : Springer Science and Business Media LLCg 15:1q 15:1x 1479-5876
8564 u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496326/x freey FULLTEXT
8564 u http://dx.doi.org/10.1186/s12967-017-1256-yx freey FULLTEXT
8564 u https://doi.org/10.1186/s12967-017-1256-y
8564 8u https://lup.lub.lu.se/record/7d4eeef6-5d4d-4877-8fb6-1b1099c0b9d2
8564 8u https://doi.org/10.1186/s12967-017-1256-y
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:136267939

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy